Immune Therapeutics, Inc. (IMUN) financial statements (2021 and earlier)

Company profile

Business Address 2431 ALOMA AVE #124
WINTER PARK, FL 32792
State of Incorp. FL
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 00000
Cash and cash equivalents 00000
Receivables     0
Inventory, net of allowances, customer advances and progress billings (0)00  
Inventory (0)00  
Other undisclosed current assets 0    
Total current assets: 00000
Noncurrent Assets
Property, plant and equipment 00000
Intangible assets, net (including goodwill)     (2)
Intangible assets, net (excluding goodwill)     (2)
Other undisclosed noncurrent assets 00002
Total noncurrent assets: 00000
TOTAL ASSETS: 00000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 75553
Accounts payable 32222
Accrued liabilities 53231
Debt 65543
Derivative instruments and hedges, liabilities 11   
Other undisclosed current liabilities 0 2  
Total current liabilities: 14111196
Noncurrent Liabilities
Total liabilities: 14111196
Stockholders' equity
Stockholders' equity attributable to parent, including: (14)(11)(6)(5)(6)
Common stock 00000
Additional paid in capital 371370367360343
Accumulated deficit (385)(381)(373)(366)(350)
Other undisclosed stockholders' equity attributable to parent 00(0)00
Stockholders' equity attributable to noncontrolling interest   (5)(4)(0)
Total stockholders' equity: (14)(11)(11)(9)(6)
TOTAL LIABILITIES AND EQUITY: 00000

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues  0 00
Cost of revenue
(Cost of Goods and Services Sold)
  (0)(2)(3) 
Gross profit:  0(2)(3)0
Operating expenses (3)(4)(6)(14)(16)
Other undisclosed operating income   23 
Operating loss: (3)(4)(6)(14)(16)
Nonoperating expense (1)(5)(2)(6)(1)
Investment income, nonoperating  (3)   
Interest and debt expense (1)(1)1(0)(1)
Loss before gain (loss) on sale of properties: (4)(9)(7)(20)(18)
Other undisclosed net income 11   
Net loss: (3)(9)(7)(20)(18)
Net income attributable to noncontrolling interest  0   
Other undisclosed net income (loss) attributable to parent   (1)01
Net loss attributable to parent: (3)(8)(8)(20)(17)
Other undisclosed net income available to common stockholders, basic   101
Net loss available to common stockholders, diluted: (3)(8)(7)(20)(16)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (3)(9)(7)(20)(18)
Comprehensive loss: (3)(9)(7)(20)(18)
Comprehensive income, net of tax, attributable to noncontrolling interest  0   
Comprehensive loss, net of tax, attributable to parent: (3)(8)(7)(20)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: